Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour
The X-AD/D-AD questionnaires were well understood and effective in capturing the experiences of xerosis and dyspigmentation in the target population in an appropriate and comprehensive way. This study supports the initial development of the questionnaires in accordance with regulatory guidelines and best practices; however, psychometric validation is required to evaluate the properties of each questionnaire and develop score interpretation guidelines.
Authors
- Emily Love
- Christopher Hartford (ORCID: https://orcid.org/0000-0001-7095-0106)
- Andrew F Alexis (ORCID: https://orcid.org/0000-0002-1351-9165)
- Gaëlle Bégo-Le-Bagousse
- Brad Shumel (ORCID: https://orcid.org/0000-0002-9285-8164)
- Benjamin Banderas (ORCID: https://orcid.org/0000-0003-2845-2634)
- Andrew Yaworsky (ORCID: https://orcid.org/0000-0003-3532-0795)
- Diana Rofail (ORCID: https://orcid.org/0000-0002-2125-4734)
- Noah A. Levit (ORCID: https://orcid.org/0000-0002-0797-5121)
- Zhixiao Wang (ORCID: https://orcid.org/0000-0003-1928-3103)
Institutions
- Fairfield University (US)
- Regeneron (United States) (US)
- Cornell University (US)
- Sanofi (France) (FR)
- Adelphi Group (United Kingdom) (GB)
- Sanofi (Mexico) (MX)
- Adelphi Laboratory Center (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1093/bjd/ljae494
- Citations
- 2
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Sanofi
- Regeneron Pharmaceuticals